This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders USA

NEXT PRICE INCREASE IN

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
New Data, Case Studies & Partners
September 10-11, 2025Boston Exhibition & Convention Center, USA
Book Now
Menu
Book
keyboard_arrow_right

Day 1- Wednesday September 10th - EST (Eastern Time, UTC-05:00

keyboard_arrow_leftSearch & Filter
close
Day 1- Wednesday September 10th - EST (Eastern Time, UTC-05:00
close
Showing 1 of 1 Streams
4:15pm - 4:40pm
Targeting Immune Cell PD-L1 with RNAi-Lipid Conjugates to Treat Refractory Cancer Patients
  • Explore innovative RNAi-lipid conjugates targeting immune cell PD-L1 for refractory cancer treatment, focusing on pre-clinical discovery and efficacy of a novel RNAi compound.
  • Delve into the compound's mechanism of action and its potential to overcome immunotherapy resistance, highlighting promising pre-clinical results.
  • Unveil the strategic clinical trial design, outlining the approach for translating this cutting-edge therapy from laboratory to patient care in challenging cancer cases.
  • Shanthi Ganesh - Director, Novo Nordisk
NextDay 2- Thursday, September 11th
Filter
Streams
Formats
Choose Day